Luye Pharma Wins FDA IND Clearance for Next-Generation CNS Drug LY03017

Reuters11-24

<a href="https://laohu8.com/S/LYPHF">Luye Pharma</a> Wins FDA IND Clearance for Next-Generation CNS Drug LY03017

Luye Pharma Group Ltd. has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug $(IND)$ application for LY03017, a next-generation serotonin 2A receptor (5-HT2AR) inverse agonist and serotonin 2C receptor (5-HT2CR) antagonist. This regulatory approval allows Luye Pharma to initiate clinical trials in the United States for LY03017, which is intended for the treatment of Alzheimer's disease psychosis, Parkinson's disease psychosis, and the negative symptoms of schizophrenia. The FDA has also exempted the single ascending dose trial in the Phase I study, permitting the company to proceed directly to multiple ascending dose and subsequent clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585837455?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 14:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585837455","market":"nz","top_or_hot":-1,"title":"Luye Pharma Wins FDA IND Clearance for Next-Generation CNS Drug LY03017","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LYPHF\">Luye Pharma</a> Wins FDA IND Clearance for Next-Generation CNS Drug LY03017\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Luye Pharma Group Ltd. has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> application for LY03017, a next-generation serotonin 2A receptor (5-HT2AR) inverse agonist and serotonin 2C receptor (5-HT2CR) antagonist. This regulatory approval allows Luye Pharma to initiate clinical trials in the United States for LY03017, which is intended for the treatment of Alzheimer's disease psychosis, Parkinson's disease psychosis, and the negative symptoms of schizophrenia. The FDA has also exempted the single ascending dose trial in the Phase I study, permitting the company to proceed directly to multiple ascending dose and subsequent clinical trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Luye Pharma Wins FDA IND Clearance for Next-Generation CNS Drug LY03017</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLuye Pharma Wins FDA IND Clearance for Next-Generation CNS Drug LY03017\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-24 14:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LYPHF\">Luye Pharma</a> Wins FDA IND Clearance for Next-Generation CNS Drug LY03017\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Luye Pharma Group Ltd. has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> application for LY03017, a next-generation serotonin 2A receptor (5-HT2AR) inverse agonist and serotonin 2C receptor (5-HT2CR) antagonist. This regulatory approval allows Luye Pharma to initiate clinical trials in the United States for LY03017, which is intended for the treatment of Alzheimer's disease psychosis, Parkinson's disease psychosis, and the negative symptoms of schizophrenia. The FDA has also exempted the single ascending dose trial in the Phase I study, permitting the company to proceed directly to multiple ascending dose and subsequent clinical trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1606","symbol_name":"中医药概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL94y30f:1","article_id":"2585837455","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585837455","pubTimestamp":1763965201,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Luye Pharma Group Ltd. has received clearance from the U.S. Food and Drug Administration  for its Investigational New Drug  application for LY03017, a next-generation serotonin 2A receptor  inverse agonist and serotonin 2C receptor  antagonist. This regulatory approval allows Luye Pharma to initiate clinical trials in the United States for LY03017, which is intended for the treatment of Alzheimer's disease psychosis, Parkinson's disease psychosis, and the negative symptoms of schizophrenia. The FDA has also exempted the single ascending dose trial in the Phase I study, permitting the company to proceed directly to multiple ascending dose and subsequent clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Lt","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1606":"中医药概念","02186":"绿叶制药","BK1583":"高瓴概念","BK1191":"制药"},"translate_title":"绿叶制药新一代中枢神经系统药物LY03017获FDA IND许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":0.9},"content_text":"Luye Pharma Wins FDA IND Clearance for Next-Generation CNS Drug LY03017\n    \n\n        Luye Pharma Group Ltd. has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug $(IND)$ application for LY03017, a next-generation serotonin 2A receptor (5-HT2AR) inverse agonist and serotonin 2C receptor (5-HT2CR) antagonist. This regulatory approval allows Luye Pharma to initiate clinical trials in the United States for LY03017, which is intended for the treatment of Alzheimer's disease psychosis, Parkinson's disease psychosis, and the negative symptoms of schizophrenia. The FDA has also exempted the single ascending dose trial in the Phase I study, permitting the company to proceed directly to multiple ascending dose and subsequent clinical trials.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585837455","isCrawlerRequest":true}